Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KN 5501

Next Previous
X
Search
Drug Profile

KN 5501

Alternative Names: Anti-CD19 CAR NK cells; KN-5501

Latest Information Update: 25 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Enricnk Biotech; Rui Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma
  • Phase 0 Autoimmune disorders

Most Recent Events

  • 20 Jun 2024 Rui Therapeutics plans a phase 0 trial for Kidney disorders (Relapsed/Refractory) in June 2024 (Parenteral, Injection) (NCT06469190)
  • 18 Jun 2024 Rui Therapeutics in collaboration with Changhai Hospital plans a phase-I trial for Autoimmune disorders (Relapsed/Refractory) in June 2024 (NCT06464679)
  • 30 Mar 2024 Rui Therapeutics plans a phase 0 trial for Immune thrombocytopenia (Treatment-experienced) and Systemic lupus erythematosus in March 2024 (Infusion, Injection) (NCT06337474)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top